Skip to content
TheBrief.Health

Living with Lung Cancer

Stories from people navigating Lung Cancer — diagnosis, treatment, caregiving, and the ordinary days in between.

7 stories

Lung cancer pathology slide beside a molecular testing report and oncology treatment notes.

Oncology

Ivonescimab Extends Survival in EGFR-Variant NSCLC

Ivonescimab plus chemotherapy prolonged median overall survival after EGFR-TKI therapy, but toxicity, generalizability and US regulatory status shape its relevance.

Rayan Salih · September 14, 2026 · 7 min

A molecular lung cancer model beside a brain scan and targeted-therapy capsule in a clinical workspace.

Oncology

Zidesamtinib Offers a Post-TKI Option in ROS1 NSCLC

Accelerated approval places zidesamtinib after a prior ROS1 tyrosine kinase inhibitor, with reported activity in systemic and intracranial disease but no randomized evidence yet.

Rayan Salih · 6 min read

Questions clinicians ask

How is zongertinib changing first-line treatment for HER2-mutant non-small cell lung cancer?
Zongertinib represents an oral targeted option for selected patients with unresectable HER2-mutant NSCLC in the first-line setting. Its FDA Accelerated Approval marks a regulatory milestone, while the broader evidence suggests oral tyrosine kinase inhibitors are expanding treatment options in both frontline and previously treated disease.
What do the 7-year CROWN study follow-up data show for oncogene-addicted NSCLC?
The long-term CROWN follow-up supports sustained disease control in the molecularly selected NSCLC population studied. These findings reinforce that effective targeted therapy can shift some oncogene-addicted advanced lung cancers toward a more chronic disease course.
What evidence supports first-line sunvozertinib for EGFR exon 20 insertion NSCLC?
Early reports suggest that sunvozertinib provides promising progression-free survival benefit when used first line in EGFR exon 20 insertion NSCLC. The evidence applies specifically to this molecular subgroup and supports continued evaluation of targeted therapy earlier in the treatment course.
Where does telisotuzumab vedotin-tllv fit in advanced non-squamous NSCLC care?
Telisotuzumab vedotin-tllv adds a biomarker-directed treatment option for selected patients with advanced non-squamous NSCLC. Its role reflects the continuing expansion of molecular and biomarker testing beyond established oncogenic drivers to identify patients who may benefit from targeted antibody-drug conjugates.

Other conditions

One story a day

The story of the day, in your inbox

One health journey each morning — no advice, no alarm, just company for the road.